Print

Purpose

The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.

Conditions

Eligibility

Eligible Ages
Between 12 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Signed informed consent and/or assent (where applicable) must be obtained prior to study participation. Participant (and parent/legal guardian for adolescents) must be able to understand and provide informed consent and assent, as applicable. If a minor participant providing assent reaches the age of legal majority (as defined by local law), he/she must be re-consented (ICF) at the next study visit. - Male or female participants who are 12 to 65 years of age, inclusive, at the time of signing informed consent/assent. - Positive allergen-specific (peanut, milk, or egg), IgE (≥ 0.35 kUA/L) at Screening Visit 1. - Positive Skin Prick Testing (SPT) for peanut, milk, or egg at Screening Visit 1. This is defined as the average diameter (longest diameter and mid-point orthogonal diameter) ≥ 4 mm wheal compared to the negative control. - A positive DBPCFC at baseline (Screening Visit 2), defined as the occurrence of dose-limiting symptoms at a single dose: - ≤ 100 mg of peanut allergen protein - ≤ 300 mg for milk or egg allergen protein - Participants must be able and willing to participate in the DBPCFC and must be willing to continue avoiding exposure to peanut, milk (cooked and uncooked), or egg (cooked and uncooked) and any other foods that they are allergic to throughout this study.

Exclusion Criteria

  • Previous use of remibrutinib or other Bruton Tyrosine Kinase (BTK) inhibitors. - History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes. - Hypersensitivity or intolerance to any of the matrix components used within the material for the DBPCFC. - Any occurrence of dose-limiting symptoms against placebo allergen at baseline DBPCFC (Screening Visit Part 1 and/or Part 2). - Medical examination, medical conditions or laboratory findings that, in the opinion of the investigator, renders the participant unsuitable for the study. Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Sub-study 1- LOU064 		Participants with peanut allergy will receive remibrutinib during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Remibrutinib
    Oral administration of remibrutinib.
    Other names:
    • LOU064
  • Drug: Placebo
    Oral administration of placebo.
Placebo Comparator
Sub-study 1- Placebo 		Participants with peanut allergy will receive matching placebo during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Placebo
    Oral administration of placebo.
Experimental
Sub-study 2- LOU064 		Participants with cow's milk allergy will receive remibrutinib during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Remibrutinib
    Oral administration of remibrutinib.
    Other names:
    • LOU064
  • Drug: Placebo
    Oral administration of placebo.
Placebo Comparator
Sub-study 2- Placebo 		Participants with cow's milk allergy will receive matching placebo during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Placebo
    Oral administration of placebo.
Experimental
Sub-study 3- LOU064 		Participants with hen's egg allergy will receive remibrutinib during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Remibrutinib
    Oral administration of remibrutinib.
    Other names:
    • LOU064
  • Drug: Placebo
    Oral administration of placebo.
Placebo Comparator
Sub-study 3- Placebo 		Participants with hen's egg allergy will receive matching placebo during the double-blind treatment period (up to Week 24), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Placebo
    Oral administration of placebo.
Experimental
Sub-study 4- LOU064 		Participants with peanut, cow's milk, and hen's egg allergy will receive remibrutinib during the double-blind treatment period (up to Week 4), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Remibrutinib
    Oral administration of remibrutinib.
    Other names:
    • LOU064
  • Drug: Placebo
    Oral administration of placebo.
Placebo Comparator
Sub-study 4- Placebo 		Participants with peanut, cow's milk, and hen's egg allergy will receive matching placebo during the double-blind treatment period (up to Week 4), followed by open-label remibrutinib treatment through Week 52.
  • Drug: Placebo
    Oral administration of placebo.

Recruiting Locations

California Allergy and Asthma Medical Group
Los Angeles, California 90025
Contact:
Vivienne An
+1 310 966 9050
viviennean@calallergy.com

National Allergy and Asthma Research LLS
North Charleston, South Carolina 29420
Contact:
Faye Singleton
+1 843 820 1036
fsingleton@nationalallergyandent.com

Western Sky Medical Research
El Paso, Texas 79924
Contact:
Laura Herrera
lherrera@westernskymed.com

More Details

Status
Recruiting
Sponsor
Novartis Pharmaceuticals

Study Contact

Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com

Detailed Description

This study is a Phase III, 52-week, multi-center, placebo controlled pivotal study to evaluate the efficacy and safety of remibrutinib compared to placebo in adolescent and adult participants with peanut, milk, or egg IgE-mediated allergy. This study will be conducted in 4 Sub-studies: Sub-study 1 to evaluate response to peanut allergen at Week 24, Sub-study 2 to evaluate response to milk allergen at Week 24, Sub-study 3 to evaluate response to egg allergen at Week 24, and Sub-study 4 to evaluate response to peanut or milk, or egg allergen at Week 4. Treatment period 1: Participants will receive one of the two treatment groups, double-blind remibrutinib or placebo, for a period up to 24 weeks for Sub-studies 1, 2, and 3, and up to 4 weeks for Sub-study 4. Treatment period 2: For all Sub-studies, the open label period starts at Week 24, except for Sub-study 4, where the open label period starts at Week 4. Participants from each Sub-study will continue in the study and receive, or initiate, active open label remibrutinib until Week 52. Following completion of the treatment period 2, eligible participants may enroll in a separate open-label post-trial access study and receive remibrutinib to evaluate long-term treatment effects. Participants who do not enroll in the post-trial access study will enter a 4-week safety follow-up period off treatment, during which adverse events will be monitored.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.